---
title: >-
  Persistent Inadequate Disease Control and Therapeutic Inertia in
  Moderate-to-Severe Atopic Dermatitis: A 12-month Longitudinal Analysis of
  Real-world Outcomes from TARGET-DERM registry.
description: >-
  Explore this publication on real-world evidence: Persistent Inadequate Disease
  Control and Therapeutic Inertia in Moderate-to-Severe Atopic Dermatitis: A…
date: '2023-01-01'
category: Publications
tags:
  - Approval / Commercialization
  - Care
  - Atopic Dermatitis (AD)
  - Health System Partner
  - Pharma Partner
  - Poster Presentation
  - RAD Conference
  - Dermatology
canonical_url: >-
  https://www.pedestalhealth.com/resources/publications/approval-commercialization/persistent-inadequate-disease-control--2023-rad-conference/
source: Pedestal Health
license: © 2026 Pedestal Health. All rights reserved.
slug: persistent-inadequate-disease-control--2023-rad-conference
id: LWqU8BAzz9HlyjSpI2VtT
contentType: article
---

## Challenge

This is a RAD Winter 2023 presentation of the same persistent inadequate disease control study as Row 20 (Fall Clinical 2024). Earlier version of the analysis characterizing the prevalence of therapeutic inertia using clinician-reported outcomes.

## Solution

TARGET-DERM AD registry used to measure the proportion of patients with moderate-to-severe AD failing to achieve AHEAD disease control targets at 3–12 months without treatment modification.

## Impact

Multi-venue dissemination of therapeutic inertia prevalence findings strengthens the evidence base for prescriber education and reinforces the commercial case for high-efficacy AD therapies that reliably achieve treat-to-target thresholds.

### [Keith D. Knapp](/people/keith-knapp/)

### [Breda Munoz](/people/breda-munoz/)

![Breda Munoz, PhD — Profile Photo](https://images.ctfassets.net/h4s3ip99qawo/3H1T2mfvSNFj6w9tulnreq/a74ae05fe53e400f176d4e9c617b8fb8/breda-munoz.jpg)

### [Julie M. Crawford](/people/julie-crawford/)